Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. (Q38497851)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26000725%20AND%20SRC:MED&resulttype=core&format=json

20 November 2019

review article

1 reference

title

Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26000725%20AND%20SRC:MED&resulttype=core&format=json

20 November 2019

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26000725%20AND%20SRC:MED&resulttype=core&format=json

20 November 2019

author name string

Richard W Childs

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26000725%20AND%20SRC:MED&resulttype=core&format=json

20 November 2019

publication date

22 May 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26000725%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Drug Discovery

20 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26000725%20AND%20SRC:MED&resulttype=core&format=json

20 November 2019

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26000725%20AND%20SRC:MED&resulttype=core&format=json

20 November 2019

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26000725%20AND%20SRC:MED&resulttype=core&format=json

20 November 2019

page(s)

487-498

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26000725%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrd4506

20 November 2019

exact match

0 references

cites work

Human Natural Killer Cells: Origin, Clonality, Specificity, and Receptors

1 reference

The trafficking of natural killer cells

31 March 2020

1 reference

Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells

31 March 2020

1 reference

Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity

31 March 2020

1 reference

„Natural” killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell

31 March 2020

1 reference

„Natural”︁ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype

31 March 2020

1 reference

Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function

31 March 2020

1 reference

Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen.

31 March 2020

1 reference

Line of attack: NK cell specificity and integration of signals

31 March 2020

1 reference

In search of the 'missing self': MHC molecules and NK cell recognition

31 March 2020

1 reference

Human NK cell education by inhibitory receptors for MHC class I.

31 March 2020

1 reference

Licensing of natural killer cells by host major histocompatibility complex class I molecules

31 March 2020

1 reference

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

31 March 2020

1 reference

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

31 March 2020

1 reference

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

31 March 2020

1 reference

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

31 March 2020

1 reference

Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients

31 March 2020

1 reference

A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer

31 March 2020

1 reference

Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers.

31 March 2020

1 reference

Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'

31 March 2020

1 reference

Differential effects of interleukin-15 and interleukin-2 on differentiation of bipotential T/natural killer progenitor cells

31 March 2020

1 reference

A programmed switch from IL-15- to IL-2-dependent activation in human NK cells.

31 March 2020

1 reference

Interleukin (IL)-2 and IL-15 have different effects on human natural killer lymphocytes

31 March 2020

1 reference

A potential role for interleukin-15 in the regulation of human natural killer cell survival

31 March 2020

1 reference

Safety and immunologic effects of IL-15 administration in nonhuman primates

31 March 2020

1 reference

Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer

31 March 2020

1 reference

Therapeutic applications: natural killer cells in the clinic.

31 March 2020

1 reference

Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action

31 March 2020

1 reference

IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization

31 March 2020

1 reference

IL-15R -IgG1-Fc Enhances IL-2 and IL-15 Anti-tumor Action through NK and CD8+ T Cells Proliferation and Activation

31 March 2020

1 reference

Interleukin-15 biology and its therapeutic implications in cancer

31 March 2020

1 reference

Interleukin-12 receptor beta2: from cytokine receptor to gatekeeper gene in human B-cell malignancies

31 March 2020

1 reference

Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes

31 March 2020

1 reference

IL-12 directs further maturation of ex vivo differentiated NK cells with improved therapeutic potential

31 March 2020

1 reference

Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma

31 March 2020

1 reference

A single administration of recombinant human interleukin-12 is associated with increased expression levels of interferon-gamma and signal transducer and activator of transcription in healthy subjects

31 March 2020

1 reference

Multilineage hematopoietic recovery with concomitant antitumor effects using low dose Interleukin-12 in myelosuppressed tumor-bearing mice

31 March 2020

1 reference

Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effects

31 March 2020

1 reference

Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

31 March 2020

1 reference

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

31 March 2020

1 reference

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

31 March 2020

1 reference

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

31 March 2020

1 reference

Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report

31 March 2020

1 reference

Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response

31 March 2020

1 reference

Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences.

31 March 2020

1 reference

Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.

31 March 2020

1 reference

PD-1 and its ligands in tolerance and immunity

31 March 2020

1 reference

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

31 March 2020

1 reference

PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection.

31 March 2020

1 reference

Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD.

31 March 2020

1 reference

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

31 March 2020

1 reference

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

31 March 2020

1 reference

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

31 March 2020

1 reference

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma

31 March 2020

1 reference

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

31 March 2020

1 reference

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells

31 March 2020

1 reference

Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo

31 March 2020

1 reference

In vivo tumor cell rejection induced by NK cell inhibitory receptor blockade: maintained tolerance to normal cells even in the presence of IL-2.

31 March 2020

1 reference

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma

31 March 2020

1 reference

Anti-CD20 antibody therapy for B-cell lymphomas

31 March 2020

1 reference

A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease

31 March 2020

1 reference

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

31 March 2020

1 reference

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

31 March 2020

1 reference

Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.

31 March 2020

1 reference

Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment

31 March 2020

1 reference

FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.

31 March 2020

1 reference

Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production

31 March 2020

1 reference

Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition

31 March 2020

1 reference

Death receptor-induced cell killing

31 March 2020

1 reference

Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells

31 March 2020

1 reference

Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.

31 March 2020

1 reference

Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors.

31 March 2020

1 reference

Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling

31 March 2020

1 reference

NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities

31 March 2020

1 reference

Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate

31 March 2020

1 reference

Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.

31 March 2020

1 reference

Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity

31 March 2020

1 reference

Differential effects of selenite and selenate on human melanocytes, keratinocytes, and melanoma cells

31 March 2020

1 reference

Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells.

31 March 2020

1 reference

Differential effects of selenium on benign and malignant prostate epithelial cells: stimulation of LNCaP cell growth by noncytotoxic, low selenite concentrations

31 March 2020

1 reference

Selenite induces posttranscriptional blockade of HLA-E expression and sensitizes tumor cells to CD94/NKG2A-positive NK cells.

31 March 2020

1 reference

Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation

31 March 2020

1 reference

Bringing natural killer cells to the clinic: ex vivo manipulation

31 March 2020

1 reference

Replicative potential of human natural killer cells

31 March 2020

1 reference

Highly activated and expanded natural killer cells for multiple myeloma immunotherapy

31 March 2020

1 reference

Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells

31 March 2020

1 reference

Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications

31 March 2020

1 reference

Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy

31 March 2020

1 reference

Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells

31 March 2020

1 reference

Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells

31 March 2020

1 reference

Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells

31 March 2020

1 reference

Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy

31 March 2020

1 reference

Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method

31 March 2020

1 reference

A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies

31 March 2020

1 reference

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

31 March 2020

1 reference

Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow

31 March 2020

1 reference

Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7.

31 March 2020

1 reference

The IL-12 signature: NK cell terminal CD56+high stage and effector functions

31 March 2020

1 reference

NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17).

31 March 2020

1 reference

Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein

31 March 2020

1 reference

Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein

31 March 2020

1 reference

Expansion of a unique CD57⁺NKG2Chi natural killer cell subset during acute human cytomegalovirus infection

31 March 2020

1 reference

Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients

31 March 2020

1 reference

CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia

31 March 2020

1 reference

Interleukin-12 is chemotactic for natural killer cells and stimulates their interaction with vascular endothelium

31 March 2020

1 reference

12 December 2020

Human natural killer cells: origin, clonality, specificity, and receptors

1 reference

12 December 2020

Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignancies.

1 reference

12 December 2020

Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response

1 reference

12 December 2020

Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo

1 reference

12 December 2020